Últimas noticias sobre Pelthos Therapeutics (AMEX:PTHS) Bolsa

Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.58%</li>
<li>UBS analyst David Vogt maintained a Neutral rating and cut the price target from $37 to $26 on May 29, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Citigroup analyst Asiya Merchant maintained a Neutral rating and slashed the price target from $29 to $27.5 on May 29, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On May 28, HP reported worse-than-expected second-quarter adjusted EPS results and issued third-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708">latest HPQ news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065636/image-74.png" alt="" class="wp-image-976317" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065636/image-74.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065636/image-74-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065636/image-74-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.68%</li>
<li>Mizuho analyst Vijay Rakesh maintained a Neutral rating and raised the price target from $72 to $75 on July 1, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Barclays analyst Tom O'Malley maintained an Underweight rating and increased the price target from $45 to $52 on May 8, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 29, Skyworks Solutions named Robert Schriesheim as interim CFO.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708">latest SWKS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="910" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065719/image-75.png" alt="" class="wp-image-976319" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065719/image-75.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065719/image-75-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065719/image-75-768x694.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></figure>
<h3 class="wp-block-heading">Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 2.76%</li>
<li>Stifel analyst David Grossman maintained a Hold rating and cut the price target from $18 to $17 on April 21, 2025. This analyst has an accuracy rate of 66%.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and slashed the price target from $25 to $18 on April 21, 2025. This analyst has an accuracy rate of 82%.</li>
<li>Recent News: On June 18, Infosys and Adobe announced a strategic collaboration to jointly transform the marketing life cycle of global brands with AI. </li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708">INFY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0708"><img loading="lazy" decoding="async" width="902" height="808" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065805/image-76.png" alt="" class="wp-image-976323" style="width:604px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065805/image-76.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065805/image-76-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/08065805/image-76-768x688.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li>T<a href="https://www.benzinga.com/markets/equities/25/07/46289573/trump-tariffs-sink-dow-over-400-points-investor-sentiment-declines-but-fear-greed-index-remains-in-extreme-greed-zone">rump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear &amp; Greed Index Remains In &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

Long Ideas

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

INFY

SWKS

Wall Street's Most Accurate Analysts Spotlight On 3 Tech Stocks Delivering High-Dividend Yields

Endeavour Silver Produces 2.5M AgEq Oz in Q2 2025, Driven by Kolpa Integration; Silver Output Hits 1.48M Oz, Gold at 7,755 Oz

HC Wainwright &amp; Co. analyst Sean Lee maintains Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) with a Buy and raises the price target from $1.1 to $1.4.

SENS

HC Wainwright & Co. Maintains Buy on Senseonics Holdings, Raises Price Target to $1.4

Brookdale Reports June 2025 Occupancy Rise: Month-End Consolidated Rate Hits 82.2%, Up 230 bps YoY And 70 bps Sequentially

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Neutral.

Downgrades

Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Downgrades Core Scientific to Neutral

BKNG moves up 1.2% after TradePulse Alert on down day for broad market
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/07203611/Screenshot-2025-07-07-at-4.33.22%E2%80%AFPM-974x1024.png" alt="" class="wp-image-15429" /></figure>
Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:41 AM on July 7th, a significant trading signal occurred for Booking Holdings Inc., (BKNG) as it demonstrated a Power Inflow at a price of $5749.69. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $5749.69. The returns on the High price ($5819.01) and Close price ($5815.92) after the Power Inflow are respectively 1.2% and 1.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

BKNG

Booking Holdings Stock Up 1.2% After Key Trading Signal

Chardan Capital analyst James McIlree maintains Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Buy and maintains $20 price target.

CLSK

Chardan Capital Maintains Buy on Cleanspark, Maintains $20 Price Target

TD Bank Launches Generative AI Virtual Assistant To Boost TD Securities Productivity

D. Boral Capital analyst Jason Kolbert upgrades Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) from Hold to Buy and announces $20 price target.

Upgrades

ARTL

D. Boral Capital Upgrades Artelo Biosciences to Buy, Announces $20 Price Target

GRMN

Garmin Smartwatches Adds Turn-By-Turn Directions With Google Maps In Connect IQ Store

WIIM

PROK

ProKidney shares are trading higher after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.

<ul>
<li>Honeywell continues to simplify and optimize its business as part of a portfolio evaluation initiated in early 2024</li>
<li>Following the planned separations, Honeywell will become a pure-play automation business focused on building automation, process automation and technologies and industrial automation</li>
<li>Industry veteran Jim&nbsp;Masso appointed to lead Honeywell's process automation business</li>
</ul>

Honeywell To Explore Strategic Alternatives For Productivity Solutions And Services And Warehouse And Workflow Solutions Businesses Ahead Of 2026 Breakup

Willis, a WTW business (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>), has launched <a href="https://www.globenewswire.com/Tracker?data=DcKyKNR-bIdG6TNxWBtaZWNSwIF1uTnJHz4Ui2PY2z15k6BHu7X-KdmJsr2XqARpEkoLQFRDoEtnE7No9jo7SVddHi_PsezPaqAPXSV5wd4YEaFCRmivxB8o9Hkp4s5QP_aJ8EqhtCI_l4uNhc9pDQ==">‘Undercover'</a>, a new $200 million facility, combining coverage for a range of geopolitical exposures faced by cargo owners worldwide.
Developed by Willis in a joint proposition with specialist insurer, Markel, Undercover offers a unique approach to the risk transfer of cargo, war on land, terrorism, political violence and confiscation coverage, with sections of coverage selected based on the individual needs of the client. This single-facility approach minimizes coverage gaps and reduces the likelihood of claims disputes, as well as removing the need to establish the motivation for a claim.
In challenging times of political instability, Undercover offers certainty of cover to cargo owners. It also provides protection from fluctuating insurance costs when country risk ratings change, as cargo cover is frequently provided on a global basis.

New WTW-Markel Insurance Plan Offers Tailored Coverage for War, Terror, and Confiscation Threats

United Homes Group Reports Q2 2025 Preliminary Results: Net New Orders Down 5.9%, Closings Down 10.1%, Starts Up 2.9% Year-Over-Year

MASS

908 Devices Launches VipIR, Industry-First 3-in-1 Handheld Analyzer With Integrated FTIR, Raman, and Smart Spectral Processing for Field Chemical ID

Larimar Therapeutics, Inc. (Larimar) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin (FXN) protein replacement therapy designed to address the underlying cause of Friedreich's ataxia (FA). These data were included in the briefing package reviewed by the U.S. Food and Drug Administration (FDA) in support of potentially using skin FXN concentrations as a reasonably likely surrogate endpoint (RLSE) for Larimar's registrational program seeking accelerated approval for nomlabofusp.
The articles, now available online, are titled:
<ul>
<li>"Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non‑clinical Studies of Friedreich's Ataxia" (<a href="https://link.springer.com/article/10.1208/s12248-025-01093-y">link</a>)</li>
<li>"Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria" (<a href="https://link.springer.com/article/10.1208/s12248-025-01054-5">link</a>)</li>
</ul>

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Highlights Data for Rare Disease Drug Nomlabofusp in FDA Briefing

Driven by retailer demand for greater food safety and transparency, cheese producers worldwide are lining up to join the rapidly growing ReposiTrak Traceability Network
ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), the world's largest food traceability and regulatory compliance network, leveraging its established inventory management and out-of-stock reduction SaaS platform, is proud to add 31 cheese suppliers to the queue of companies joining the ReposiTrak Traceability Network&#xAE; (RTN). These companies will efficiently exchange intricate, FDA-required Key Data Elements (KDEs) for each Critical Tracking Event (CTE) in their supply chains, with the goal of meeting the growing traceability demands of their retail customers.

TRAK

ReposiTrak Adds 31 Cheese Suppliers To Queue Of Companies Joining ReposiTrak Traceability Network

JinkoSolar Commissions 21.6 MWh Energy Storage Systems With Distributed Energy Infrastructure Under SMART Program

Biotech

General

BCLI

BrainStorm Cell Therapeutics Acknowledges FDA Consideration Of Citizen Petition Requesting New Review Of Data Supporting NurOwn; Says Will Continue With Planned Phase 3b Trial

Comments

Pelthos Therapeutics

Noticias

Últimas noticias sobre Pelthos Therapeutics (AMEX:PTHS) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL